3rd Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$1,460,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

ACA Pharmaceutical Industry Fee Exclusions Anti-Inversion Tax H.R.3618 - Orphan Drug Fairness Act S.1906 - Orphan Drug Fairness Act Medical Device Tax Repeal & Suspension Section 385 Tax Regulation H.R.2315 - Mobile Workforce State Income Tax Simplification Act of 2015

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
JASON BENJAMIN VAN PELT —

Contacted: State, Dept of (DOS); Office of Management & Budget (OMB); White House Office; U.S. Agency for International Development (USAID); SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: H.R. 3618 (114th), S. 1906 (114th), H.R. 2315 (114th)

Trade (domestic/foreign) TRD

Free Trade Agreements: - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and market Access Issues Trans-Pacific Partnership FTA Sub-standards Medicines Quality of Medicines . Trade Promotion Authority . Trans-pacific Partnership . Trans Atlantic Trade and Investment Partnership International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Colombia Intellectual Property Regulatory Cooperation

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SARAH HALLER —
SHAWN O'NEAIL —
JASON BENJAMIN VAN PELT —

Contacted: U.S. Agency for International Development (USAID); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office; U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Food & Drug Administration (FDA); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC)

Copyright/Patent/Trademark CPT

HR3116 MODDERN Cures Act of 2013 S.632 STRONG Patents Act of 2015 HR.9 Innovation Act S.1137 PATENT Act Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection Issues Patient Litigation Reform and Issues Related to Post Grant Proceedings at PTO Neonates BPCIA Hatch-Waxman Patents

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
JASON BENJAMIN VAN PELT —

Contacted: HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Commerce, Dept of (DOC); White House Office; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); SENATE; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID)

Bills named: H.R. 3116 (114th), S. 1137 (114th), S. 632 (114th), H.R. 9 (114th)

Health Issues HCR

S.2041/HR 5182 - Promoting Life-Saving New Therapies for Neonates Act of 2015 S.481 - Improving Regulatory Transparency for New Medical Therapies Act H.R.2841 - Fair Access for Safe and Timely Generics Act of 2015 H.R.6 - 21st Century Cures Act Cell & Gene Therapy Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act FSA/HSA - Support reinstating coverage of OTC products HR351/S351 - Medicine Decisions Act of 2011 (IPAB) 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program MDUFA (Medical Device User Fee Act) Implementation Drug Importation Reimbursement for medical devices GMP related to manufacturing sites Biosimilars PDUFA Low-income Subsidy in Part D REMS Creates Act FCLCA Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Generic Drugs Medicaid FDA Regulations of Lab Developed Tests (LDT) Reimbursement for LDTs Part B Demo Regrow Act IPAB Generic Drug Labeling H.R.4784 Lower Drug Costs through Competition Act S.2615 Increasing Competition in Pharmaceuticals Act Outcomes-based Contracting Expanded Access PREA/BPCA BSUFA GDUFA Truthful, Non-Misleading Drug Information

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SARAH HALLER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
WENDY P SUSSMAN —
JASON BENJAMIN VAN PELT —

Contacted: U.S. Agency for International Development (USAID); Office of Management & Budget (OMB); SENATE; State, Dept of (DOS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); White House Office; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Bills named: S. 2615 (114th), H.R. 6 (114th), S. 481 (114th), S. 2041 (114th), H.R. 4784 (114th), H.R. 5182 (114th), H.R. 351 (114th), H.R. 2841 (114th)

Medicare/Medicaid MMM

Biosimilars Medicare Part D Drug Pricing Part B CMMI Part B Demonstration Project Generics Innovative Pharmaceuticals

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
WENDY P SUSSMAN —
JASON BENJAMIN VAN PELT —

Contacted: U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; White House Office; SENATE; State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB)

Budget/Appropriations BUD

FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2016 Labor HHS Appropriations Bill Reconciliation Gx Drug Labeling Biosimilars

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
WENDY P SUSSMAN —
JASON BENJAMIN VAN PELT —

Contacted: Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR); White House Office; SENATE; State, Dept of (DOS); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.